SCHEMBL7135231

SCHEMBL7135231

CC(C)OCCCNCc1c[c]ccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 2/20 0.45
HDAC1 Q13547 1/20 0.41
SCN8A Q9UQD0 3/20 0.40
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP3 P42574 1/20 0.39
BLM P54132 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAOA P21397 1/20 0.38
CHRM2 P08172 1/20 0.37
LMNA P02545 2/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
DRD4 P21917 1/20 0.36
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6636493 0.79 DRD2 (0.49) SMN1; SMN2ALDH1A1MAPK1GAADRD4
SCHEMBL6634166 0.79 HRH4 (0.47) SMN1; SMN2TDP1MAOACHRM2LMNA
SCHEMBL6637251 0.77 L3MBTL1 (0.40) HDAC1MAPTMAPK1NPSR1TDP1
SCHEMBL2183492 0.77 L3MBTL1 (0.47) ALDH1A1SCN8ATDP1MAOACHRM2
SCHEMBL6636827 0.77 HRH4 (0.54) SMN1; SMN2MAOACHRM2LMNA
SCHEMBL1166414 0.77 HPGD (0.33) MAPTMAPK1CASP3BLMNPSR1
SCHEMBL6637837 0.76 CYP1A2 (0.54) SMN1; SMN2MAOACHRM2LMNAKMT2A
SCHEMBL6638323 0.75 MEN1 (0.42) SMN1; SMN2MAPTTDP1MAOACHRM2
SCHEMBL27549496 0.74 SIGMAR1 (0.61) MAPTMAOACHRM2GAA
SCHEMBL1040808 0.73 OPRK1 (0.40) SMN1; SMN2ALDH1A1HDAC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed